Drugs / CTH120
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06480968 | Jun 2023 → Nov 2024 | fragile X syndrome | Connecta Therapeutics, S.L. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07654114 | May 2026 → May 2027 expected | fragile X syndrome | Connecta Therapeutics, S.L. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-07-02 | Connecta Therapeutics, S.L. | Results CONNECTA Therapeutics and Centre for Genomic Regulation to Present First-in-Class Program CTH120 for Fragile X Syndrome at FENS Forum 2026 connectatherapeutics.com ↗
Restoration of cognitive and behavioral deficits in the Fmr1 -KO model, demonstrating improvement in key functional impairments associated with FXS |
| 2025-03-04 | Connecta Therapeutics, S.L. | Results CONNECTA Therapeutics announces positive results from Phase I study of neurodevelopmental disorders drug candidate, CTH120 connectatherapeutics.com ↗
CONNECTA Therapeutics has announced positive results from its Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetics profile of its drug candidate CTH120 in adult volunteers. |
| 2023-06-06 | Connecta Therapeutics, S.L. | Regulatory Connecta Therapeutics starts clinical trials for its Fragile X syndrome drug connectatherapeutics.com ↗ |
| 2021-09-07 | Connecta Therapeutics, S.L. | Regulatory Connecta Therapeutics drug for fragile X syndrome receives orphan designation from European Medicines Agency connectatherapeutics.com ↗
Connecta Therapeutics has received approval as orphan drug from the European Medicines Agency (EMA) to treat fragile X syndrome (FXS), the leading cause of hereditary intellectual disability. |
All press releases naming this drug 9 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CTH120 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06480968 ↗ |
| Route | Oral | “Capsules of CTH120 will be administered by the oral route” NCT07654114 ↗ |